|11/17/14||Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)|
|-- Andexanet Alfa Rapidly Reversed the Anticoagulant Effect of the Factor Xa Inhibitor Eliquis (apixaban) Among All Study Participants --
-- Data Presented Today during American Heart Association 2014 Scientific Sessions: "Clinical Science: Special Reports" Session --
SOUTH SAN FRANCISCO, Calif., PRINCETON, N.J., and NEW YORK, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA), Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced resul... |
|11/10/14||Portola Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update|
|Conference Call Today at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today provides a corporate update and reports its financial results for the quarter ended September 30, 2014.
"The third quarter marked another successful period of execution for Portola as we achieved a number of milestones across our three wholly-owned clinical programs. We announced positive Phase 3 study results with our universal Factor Xa inhibitor... |
|11/06/14||Portola Pharmaceuticals Announces Upcoming Presentations at the American Society of Hematology 2014 Annual Meeting|
|SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that its programs in thrombosis and hematology will be highlighted in poster sessions at the upcoming American Society of Hematology (ASH) Annual Meeting, which is taking place from December 6-9 in San Francisco. Presentations will include results from a Phase 2 proof-of-concept study of andexanet alfa, an FDA-designated breakthrough therapy and potential first-in-class Factor Xa i... |
|11/06/14||Portola Pharmaceuticals to Present at the Credit Suisse 2014 Healthcare Conference|
|SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, at 9:30 a.m. Mountain Time in Phoenix.
The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals i... |
|11/03/14||Portola Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Host Conference Call on Monday, November 10, 2014|
|SOUTH SAN FRANCISCO, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended September 30, 2014 and provide a general business overview on Monday, November 10, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Conference Call Details
To access the live conference call, please dial (877) 415-3183 from the U.S. and Canada, or +1(857)... |